{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:19:32Z","timestamp":1788538772205,"version":"build-2803163510"},"reference-count":31,"publisher":"SLACK, Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HLRP: Health Literacy Research and Practice"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Plain language summaries (PLSs) play a crucial role in communicating complex clinical trial information to patients and the public. Due to the European Union Clinical Trials Regulation (EU CTR) 536\/2014 requirement to disclose PLSs in parallel with the technical results, clinical trial sponsors will need to develop such summaries swiftly and efficiently, while avoiding potential obstacles. Their creation can be challenging for sponsor company stakeholders who typically use highly technical, scientific language.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Brief Description of Activity:<\/jats:title>\n                    <jats:p>This manuscript describes the PLS development and review process established at our company. It also considers the collection of feedback via an anonymous survey, both of which were intended to optimize PLS preparation. Finally, it explores internal stakeholder preparedness for EU CTR requirements, and further opportunities to enhance PLS quality to better support patient centricity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implementation:<\/jats:title>\n                    <jats:p>We observed a learning curve among stakeholders (content contributors and reviewers) and an enhanced appreciation for the PLS process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This resulted in improved best practice principles for PLS writing, such as describing only the primary endpoint(s) and adverse drug reactions. The process of PLS development was streamlined following implementation of stakeholders' feedback received in PLS surveys circulated in 2023 and 2024. This led to increased satisfaction with the instructions provided for stakeholders and with the processes for PLS development, including the company-developed PLS template and glossary of plain language terms. Here we suggest that regularly adjusting PLS tools based on continuous feedback from internal stakeholders contributes to a more efficient and clear process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons Learned:<\/jats:title>\n                    <jats:p>Optimization of the PLS development process using feedback from internal stakeholders supports efficiency, clarity, and patient-centricity, as well as ensuring preparedness for EU CTR requirements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/24748307-20260410-02","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:50:03Z","timestamp":1788537003000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Development of Plain Language Summaries of Clinical Trial Results"],"prefix":"10.3928","volume":"10","author":[{"given":"Jennifer","family":"Doralt","sequence":"first","affiliation":[{"name":"Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernie","family":"Keohane","sequence":"additional","affiliation":[{"name":"Xogene Services LLC, Englewood, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"McGilvray","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pobinger","sequence":"additional","affiliation":[{"name":"Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislava G.","family":"Pavlova","sequence":"additional","affiliation":[{"name":"Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1409364"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-019-00285-0"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-022-00358-6"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2058812"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.56012\/vmag9372"},{"key":"e_1_3_1_7_1","author":"European Commission","year":"2018","unstructured":"European Commission. (2018, February 22). Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No536\/2014 on clinical trials on medicinal products for human use Version 2. Summaries of clinical trial results for laypersons. https:\/\/health.ec.europa.eu\/system\/files\/2020-02\/2017_01_26_summaries_of_ct_results_for_laypersons_0.pdf","journal-title":"Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No536\/2014 on clinical trials on medicinal products for human use Version 2. Summaries of clinical trial results for laypersons"},{"key":"e_1_3_1_8_1","author":"European Commission Clinical Trials Expert Group (EC CTEG)","year":"2021","unstructured":"European Commission Clinical Trials Expert Group (EC CTEG) (2021, October 4). Good lay summary practice. https:\/\/health.ec.europa.eu\/document\/download\/8a42b8f5-4ec3-4667-969c-3dd89ea8b270_en","journal-title":"Good lay summary practice"},{"key":"e_1_3_1_9_1","author":"European Medicines Agency (EMA)","year":"2014","unstructured":"European Medicines Agency (EMA). (2014, May 27). Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing directive 2001\/20\/EC. Retrieved February 8, 2024 from https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-1\/reg_2014_536\/reg_2014_536_en.pdf","journal-title":"Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing directive 2001\/20\/EC"},{"key":"#cr-split#-e_1_3_1_10_1.1","unstructured":"The European Parliament and the Council of the European Union. (2014). Regulation"},{"key":"#cr-split#-e_1_3_1_10_1.2","unstructured":"(EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use and repealing Directive 2001\/20\/EC (Text with EEA relevance). Retrieved from https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/HTML\/?uri=CELEX:32014R0536"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1615441"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1179\/2047480615Z.000000000324"},{"key":"e_1_3_1_13_1","author":"Health Research Authority (HRA)","year":"2025","unstructured":"Health Research Authority (HRA). (2025, January 7). Writing a plain language (lay) summary of your research findings. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/best-practice\/writing-plain-language-lay-summary-your-research-findings\/","journal-title":"Writing a plain language (lay) summary of your research findings"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3218"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-017-0064-0"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.3928\/24748307-20240218-01"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1997221"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.3928\/24748307-20210524-01"},{"key":"e_1_3_1_19_1","author":"The MRCT Center of Brigham and Women's Hospital and Harvard","year":"2024","unstructured":"The MRCT Center of Brigham and Women's Hospital and Harvard. (2024). Health literacy in clinical research: Plain language. https:\/\/mrctcenter.org\/health-literacy\/tools\/overview\/plain-language\/","journal-title":"Health literacy in clinical research: Plain language"},{"key":"e_1_3_1_20_1","volume-title":"Return of aggregate results to participants guidance document version 3.1","author":"MRCT Center Post-Trial Responsibilities Workgroup","year":"2017","unstructured":"MRCT Center Post-Trial Responsibilities Workgroup. (2017, December 6). Return of aggregate results to participants guidance document version 3.1. The MRCT Center of Brigham and Women's Hospital and Harvard. https:\/\/mrctcenter.org\/resource\/return-of-aggregate-results-to-participants-guidance-document-version-3-1\/"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037994"},{"key":"e_1_3_1_22_1","author":"Pakarinen C.","year":"2022","unstructured":"Pakarinen, C., Dewhurst, J., Bilodeau, D., Rohou, S. C., & Khawaja, S. (2022). New requirements for lay language summaries of clinical trials are here\u2014Are you prepared? https:\/\/globalforum.diaglobal.org\/issue\/may-2022\/new-requirements-for-lay-language-summaries-of-clinical-trials-are-here-are-you-prepared\/","journal-title":"New requirements for lay language summaries of clinical trials are here\u2014Are you prepared?"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-024-00700-y"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2308729"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04969-w"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.542"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.4065\/84.3.243"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1057\/palgrave.jphp.3200102"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02855-5"},{"issue":"7","key":"e_1_3_1_30_1","first-page":"41","article-title":"Layperson\/ plain language summaries: Can sponsors, CROs, and sites deliver in 2020?","volume":"17","author":"Wilcox C. S.","year":"2020","unstructured":"Wilcox, C. S., Franceschi, L., & Simmons, A. (2020). Layperson\/ plain language summaries: Can sponsors, CROs, and sites deliver in 2020? Innovations in Clinical Neuroscience, 17(7\u20139), 41\u201344 PMID:33520403","journal-title":"Innovations in Clinical Neuroscience"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-023-00531-5"}],"container-title":["HLRP: Health Literacy Research and Practice"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:50:05Z","timestamp":1788537005000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/24748307-20260410-02"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["10.3928\/24748307-20260410-02"],"URL":"https:\/\/doi.org\/10.3928\/24748307-20260410-02","relation":{},"ISSN":["2475-6024","2474-8307"],"issn-type":[{"value":"2475-6024","type":"print"},{"value":"2474-8307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}